Product Name: CASP3 Antibody
Species Reactivity: Human
Tested Applications: ELISA, WB
Applications: CASP3 antibody can be used for detection of CASP3 by ELISA at 1:62500. CASP3 antibody can be used for detection of CASP3 by western blot at 5 μg/mL, and HRP conjugated secondary antibody should be diluted 1:50,000 – 100,000.
User Note: Optimal dilutions for each application to be determined by the researcher.
Predicted Molecular Weight: 32 kDa, 32 kDa
Immunogen: Antibody produced in rabbits immunized with a synthetic peptide corresponding a region of human CASP3.
Host Species: Rabbit
Purification: Antibody is purified by protein A chromatography method.
Physical State: Lyophilized
CAS NO.: 403811-55-2
Product: 10058-F4
Buffer: Antibody is lyophilized in PBS buffer with 2% sucrose. Add 100 μL of distilled water. Final antibody concentration is 1 mg/mL.
Concentration: 1 mg/ml
Storage Conditions: For short periods of storage (days) store at 4˚C. For longer periods of storage, store CASP3 antibody at -20˚C. As with any antibody avoid repeat freeze-thaw cycles.
Clonality: Polyclonal
Conjugate: Unconjugated
Alternate Names: CASP3, CPP32, SCA-1, CPP32B
Accession NO.: NP_004337
Protein Ino: 14790119
Official Symbol: CASP3
Geneid: 836
Background: CASP3 is a protein which is a member of the cysteine-aspartic acid protease (caspase) family. Sequential activation of caspases plays a central role in the execution-phase of cell apoptosis. Caspases exist as inactive proenzymes which undergo proteolytic processing at conserved aspartic residues to produce two subunits, large and small, that dimerize to form the active enzyme. This protein cleaves and activates caspases 6, 7 and 9, and the protein itself is processed by caspases 8, 9 and 10. It is the predominant caspase involved in the cleavage of amyloid-beta 4A precursor protein, which is associated with neuronal death in Alzheimers disease. Alternative splicing of this gene results in two transcript variants that encode the same protein.
PubMed ID:http://aac.asm.org/content/43/5/1183.abstract
